Interaction between fluvoxamine and cotinine or caffeine.

Abstract

We examined the relationships between plasma fluvoxamine concentrations and plasma levels of cotinine and caffeine, respectively, under steady-state conditions in 30 patients who met DSM-IV criteria for a major depressive disorder and who were being treated with fluvoxamine. The daily dosages of fluvoxamine ranged from 50 to 200 mg (mean +/- SD 108 +/- 42 mg). Eleven patients were smokers and the remaining 19 were nonsmokers. The plasma fluvoxamine concentrations were significantly higher in nonsmokers (0.92 +/- 0.40 ng/ml/mg) than in smokers (0.56 +/- 0.28 ng/ml/mg); in addition, a trend towards negative correlations was observed between the plasma fluvoxamine concentrations and the plasma cotinine levels, although it was not significant. Significant positive correlations were found between the plasma fluvoxamine concentrations and the plasma caffeine levels. These findings are compatible with those in earlier reports that cytochrome P450 1A2 plays a major role in fluvoxamine metabolism.

• Authors: Reiji Yoshimura, Nobuhisa Ueda, Jun Nakamura, Seiji Eto, Masakazu Matsushita
• Journal: Neuropsychobiology (Neuropsychobiology) Vol. 45 Issue 1 Pg. 32-5 ( 2002) ISSN: 0302-282X [Print] Switzerland
• PMID: 11803239 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2002 S. Karger AG, Basel

Chemical References

• Antidepressive Agents, Second-Generation
• Central Nervous System Stimulants
• Caffeine
• Cytochrome P-450 CYP1A2
• Cotinine
• Fluvoxamine

Topics

• Adult
• Aged
• Antidepressive Agents, Second-Generation (blood, pharmacokinetics, therapeutic use)
• Caffeine (blood)
• Central Nervous System Stimulants (blood)
• Cotinine (blood)
• Cytochrome P-450 CYP1A2 (metabolism)
• Depressive Disorder, Major (drug therapy, metabolism)
• Drug Interactions
• Female
• Fluvoxamine (blood, pharmacokinetics, therapeutic use)
• Humans
• Male
• Middle Aged
• Smoking